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Lumican Peptides: Rational Design 
Targeting ALK5/TGFBRI
Tarsis Ferreira Gesteira1,*, Vivien J. Coulson-Thomas1,*,†, Yong Yuan1, Jianhua Zhang1, 
Helena B. Nader2 & Winston W.-Y. Kao1
Lumican, a small leucine rich proteoglycan (SLRP), is a component of extracellular matrix which also 
functions as a matrikine regulating multiple cell activities. In the cornea, lumican maintains corneal 
transparency by regulating collagen fibrillogenesis, promoting corneal epithelial wound healing, 
regulating gene expression and maintaining corneal homeostasis. We have recently shown that a peptide 
designed from the 13 C-terminal amino acids of lumican (LumC13) binds to ALK5/TGFBR1 (type1 receptor 
of TGFβ) to promote wound healing. Herein we evaluate the mechanism by which this synthetic C-terminal 
amphiphilic peptide (LumC13), binds to ALK5. These studies clearly reveal that LumC13-ALK5 form a 
stable complex. In order to determine the minimal amino acids required for the formation of a stable 
lumican/ALK5 complex derivatives of LumC13 were designed and their binding to ALK5 investigated in 
silico. These LumC13 derivatives were tested both in vitro and in vivo to evaluate their ability to promote 
corneal epithelial cell migration and corneal wound healing, respectively. These validations add to the 
therapeutic value of LumC13 (Lumikine) and aid its clinical relevance of promoting the healing of corneal 
epithelium debridement. Moreover, our data validates the efficacy of our computational approach to 
design active peptides based on interactions of receptor and chemokine/ligand.
Proteoglycans (PGs) are complex polymers composed of a core protein to which one or more glycosaminoglycan 
(GAGs) chains are covalently attached. They play a central role in physiology and disease1–6: modulating cell 
metabolism, mediating cell-cell trafficking, providing support for connective tissue and regulating of a wide range 
of effectors at both systemic and cellular levels7. Small leucine rich proteoglycans (SLRPs) are a family of proteo-
glycans with small core proteins (~40 Kd) that contain hyper variable glycosylation sites with multivalent binding 
abilities8. To date, the SLRPs family encompasses 18 genes, which are classified into five distinct subfamilies based 
on homologies at both the genomic and protein levels9,10. Lumican, a class II SLRP member, is one of the major 
proteoglycans in the corneal stroma11,12. Members of the SLRP family, including Lumican, share similar struc-
tures and are composed of a 16-residue signal peptide, a negatively charged N-terminal domain, a ten-tandem 
leucine-rich repeat region (LRR), and a C-terminal domain containing 2 conserved cysteine residues. Each LRR 
has a conserved hallmark motif LXXLXLXXNXL (L: leucine which can be substituted by isoleucine, valine or 
other hydrophobic amino acid, while X indicates any other natural amino acid). This central LRR domain is 
responsible for forming the characteristic horseshoe-shaped solenoid structure with both convex and concave 
faces9. Both N- and C-terminus domains contain conserved cysteine residues, which maintain the protein core 
conformation and stability, and may also influence ligand binding13,14. A mutation at the C-terminal domain of 
Decorin has been linked to congenital stromal dystrophy of the cornea15,16. However, a disease directly related 
to a structural mutation of Lumican is yet to be confirmed. In the cornea, Lumican acts maintaining corneal 
transparency by regulating collagen fibrillogenesis and promoting corneal epithelial wound healing via a yet to 
be fully defined mechanism(s)17,18. Lumican may also serve as a matrikine, promoting corneal epithelial wound 
healing and maintaining corneal homeostasis by modulating gene expression in both physiological and patho-
logical instances12,19,20. Recently, our group described the function of a synthetic LumC13-terminal peptide6, 
YEALRVANEVTLN (Lumikine), in binding ALK5 to promote wound healing6.
Herein, we exploited the C-terminal Lumican peptide surroundings, followed by further exploration of ALK5 
as a potential target and further developed suitable peptidomimetics of LumC-peptides. Molecular docking and 
MD simulation studies were carried out to study the interaction of the LumC-peptides and ALK5 complex, which 
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provides insights into vital binding interactions. These interaction studies not only revealed the relatively stable 
interaction of LumC peptide with ALK5 but also highlighted the significance of these interactions in activating 
ALK5. We were also able to establish the minimal amino acid sequence required for the formation of the lumican/
ALK5 complex. Validations of the peptides functions in wound healing in vivo add to the therapeutic value of 
Lumikine in promoting healing of damaged corneal epithelium.
Results
Molecular Docking. We used a modified HADDOCK benchmark for an efficient protein-peptide docking 
protocol, combining the conformational selection with induced fit21, where both receptor and ligand are inde-
pendently minimized, as well as the starting protein–ligand interaction residues. In order to verify the specificity 
of the binding of the 13 C-terminal amino acids of lumican to ALK5 we designed 13 aa peptides based on the 
surrounding C-terminal region of lumican. Our data indicates the final 5 amino acids (EVTLN) were primarily 
involved in the LumC13-ALK5 interaction. To further verify this, we generated hybrid peptides, combining the 
EVTLN region with up-stream C-terminal regions, enabling us to ascertain these are the minimal amino acids 
necessary for LumC13-ALK5 interaction, the sequence of these peptides are summarized in Table 1. For the 
LumC peptides (Table 1), all 13 residues were specified as active residues, and for ALK5 a distance threshold of 
15 Å around the GS domain was defined to select the residues that interact with the conformation obtained from 
previous work by Yamanaka, et al.6. The flexible docking performed with LumC13 returned 10 clusters, with 
82 best poses in the best scoring cluster. This cluster (cluster 1, Fig. 1, Table 2 and Supplemental Table 1) had a 
HADDOCK score of − 83.6 ± 7.3 kcal/mol. Overall, energies varied between − 50 and − 80 kcal/mol, indicating 
reasonable intermolecular affinities for all peptides docked.
As the HADDOCK score is determined for each structure after docking, a rank of the structures with the 
weighted sum of intermolecular electrostatic (Elec), van der Waals (vdw), desolvation (Dsolv) and AIR energies, 
and a buried surface area (BSA) was obtained, allowing for a comparison of values. While the LumC33ΔC20 score 
is − 77.3 ± 11.4, Lumikine (LumC13C-A) and LumikineY-F show a score of − 83.8 ± 7.1 and − 84.8 ± 7.0, respec-
tively (Table 2). The less negative values of the HADDOCK score of the LumC33ΔC20 complexes indicate a lower 
affinity between the biological partners compared to the native complex, while the LumikineY-F (LumC13A,Y-F) and 
Lumikine complexes have again a similar HADDOCK score as the LumC13 complex, illustrating again a good 
affinity between the biological partners. LumC18ΔC5 and the score of the hybrid peptides (LumC18∆C5, Hybryd 
1/3, Hybryd 2/3 and Hybryd 2/3Y-F) amount to similar score values of − 79.5 ± 1.7, − 55.8 ± 4.0, − 76.0 ± 1.6 and 
− 82.5 ± 0.5, respectively. The BSA is used to quantify the protein surfaces, which are not exposed to water. The 
LumC13 complex shows a BSA value of 1490.8 ± 109.1, while the BSA values of the LumC33ΔC20, Lumikine, 
LumikineY-F are 1375.6 ± 140.2, 1384.9 ± 79.8 and 1574.4 ± 138.3, respectively, and the LumC18ΔC5 and the score 
of the hybrid peptides exhibit a BSA score of 1450.3 ± 71.0, 1266.2 ± 138.5, 1441.9 ± 35.8 and 1284.2 ± 24.2, 
respectively (see Table 2 and Table S1). A higher BSA value enables a close proximity between the biomolecules. 
The desolvation energy, the restraints violation energy and the BSA have a good correlation with the docking 
score of the complex during docking. From Table 2, it is thus again clear that both LumC13C-A and Hybrid 2/3 
peptides would present higher affinity to ALK5, whereas hybrid 1/3 shows the lowest interaction values to ALK5.
Molecular Dynamics. Molecular dynamics (MD) calculations have been previously used in understanding 
and characterizing the structural, dynamical, and functional properties of biomolecular systems. Our group has 
recently developed its application for the rational design of lumican peptides capable of binding ALK56.
Eight sets of 100-ns simulations were performed for each of the peptide-ALK5 systems described above. All 
simulations were performed under constant temperature and pressure conditions. Visual inspection of 100 ns 
MD trajectories clearly revealed that LumC33ΔC20 monomer essentially cluster within mixed conformations, spe-
cifically around the C-terminus, leading to a large backbone root-mean-square deviation (rmsd) of 2.3 Å. We 
next clustered the similar conformations of hybrid peptides in comparison with LumC18ΔC5 using the cluster 
plugin in VMD22 with the criteria of a Cα rmsd cutoff of 1.0 Ǻ. Figure 2 shows each peptide most representative 
conformations populated. Each cluster represents a comparable structural population of ∼ 3.3%, representing 
a sum of ∼ 16.3% of all conformations. It can be seen that most representative hybrid 2/3 peptide conforma-
tions displayed little transit between conformations, with 89.4% of the second conformation of the same cluster 
grouped (Fig. 2G). It is reasonable to infer from this structural property that this peptide occurs in an oriented 
mode to ALK5, as opposed to the hybrid 1/3 (Fig. 2F), suggesting that this peptide forms a complex adopting 
multiple conformations when bound to ALK5. Moreover, the GS-domain appears to be stabilized by contacts 
among Glu2, Glu9 and Asn8 from LumC13C-A and LumikineY-F, while the mutation of a Tyr1 to phenylalanine 









Table 1.  Sequence of Lumican Peptides Designed/Analyzed.
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Figure 1. Scatter plots of global flexible docking results. Score values are represented versus RMSD over 
peptide backbone heavy atoms (rmsBB) with respect to the initial conformation. Score values are represented 
versus the ligand RMSD (l-RMSD). HADDOCK best scored poses (edge of tunnel) were subjected to MD 
simulations.
www.nature.com/scientificreports/
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in peptide LumikineY-F does not affect binding significantly. Those residues bind specifically to the GS-domain 
region (Fig. 2C,D and Supplementary Fig. 1).
The contact probability per amino acid type analysis reveals that both positively and negatively charged resi-
dues (Arg, Lys, Glu) of the peptides are involved in ALK5 binding, while significant participation of the polar (Ser, 
Thr), and hydrophobic (Leu, Pro, Val) residues is also observed. These results imply that the LumC33ΔC20 contact 
surface is more homogeneous in terms of the peptide amino acid composition, as no particular amino acid type 
shows a strong binding preference for LumC33ΔC20.
The higher contact probability of the mainly hydrophilic LumC13C-A is consistent with their frequent interac-
tion with the GS domains of ALK5. Given the more heterogeneous nature of the hybrid surface, it is likely easier 
for the hybrid N-terminus tyrosine to find a complementary binding pocket that can satisfy all or majority of the 
possible charge-charge interactions. Thus, the C-terminus (with a smaller local concentration of charged resi-
dues) appears to remain in contact with GS domain more frequently compared to the N-terminus.
Further analysis reveals that this difference is caused by the different flexibility of hybrid 2/3 conformations 
sampling, reflecting its entropy. As shown in Fig. 2, while the methionine serves as the main anchoring residue 
during simulations, the remaining residues have maintained contact profiles.
Molecular Dynamics simulations. LumC13, a peptide that binds to ALK5 and peptides derivate from 
rational design were evaluated regarding their binding/interacting potency6,23,24, to explore their potential binding 
modes with ALK5 and find out the causes of the difference from a theoretical perspective via molecular docking, 
molecular simulation, and MM-PBSA calculation. We determined the optimal binding modes of the LumC pep-
tides with ALK5 by 100 ns molecular dynamics simulations based on the docking results to explore the binding 
mechanism. Then, we ran triplicates of 100 ns MD for each complex, and conformations were analyzed for anal-
ogous differences of key residues around their apparent binding sites. In the following sections, the results from 
one of the triplicates were discussed. First, the RMSD of backbone Cα atoms were analyzed to determine if these 
systems reached equilibrium.
In Fig. 2A (Ligplot in Supplemental Fig. S1), the detailed binding modes of LumC13 peptide reveals that the 
carbonyl oxygen atom and carboxyl group of the Glu9 of LumC13 establish hydrogen bonds with the Gly188 
of ALK5 main chain. The Arg5 of LumC13 is stabilized by its main chain with Gly190, Gly325 and Met253 
via hydrogen bonds. The side chain of Tyr1 of LumC13/Lumikine is stabilized with residues ALK5 Glu247 and 
Gln250 by hydrogen bonding interaction. Finally, Asn8 of LumC13/Lumikine is anchored by hydrogen bond with 
ALK5 Ser187.
The probability of occurrence of hydrogen bonds was calculated by using the H-bonds plugin v1.2 in vmd22 
and the corresponding results of H-bonds between peptides and ALK5 are shown in Table 3. As the occurrence 
probability of the aforementioned hydrogen bonds are reasonably high (three higher than 90%, two higher than 
65%), this suggests these H-bonds exist stably. The existence of these H-bonds might lead to strong electrostatic 
interactions between receptors and donors, which will be demonstrated by results of MM-PBSA calculation.
Figure 2B shows that in the LumC33ΔC20-ALK5 complex system, one pair of hydrogen bonds exist between 
the side chain of Lys2 and the carboxyl of Glu247 and Glu250. The carbonyl oxygen atom of Glu247 also interacts 
with Ile1 through hydrogen bond. The side chains of Arg5 and Leu6 tend to form hydrogen bond with Ser191. 
In addition, the hydroxyl of Thr251 establishes a hydrogen bond with the N-gama nitrogen of His3 of LumC13.
In order to further validate the binding modes, we carried out molecular dynamics simulations to gain detailed 
information about the key residues of the active site in each complex, the electrostatic, van der Waals, solvation 
and total contribution of the residues to the binding free energy of Lumikine–ALK5 and LumC-peptides-ALK5 
interaction were calculated with the MM-PBSA method. The contributions from the residues around the 
GS-domain are shown in Fig. 3 and Table 3.
Binding energy estimation by MMPB(GB)SA. Several techniques exist to predict binding free energies 
based on MD simulations, including free energy perturbation, thermodynamic integration, molecular mechan-
ics Poisson–Boltzmann surface area (MMPBSA), and molecular mechanics generalized Born surface area 
(MMGBSA) techniques25. Although recent studies reported encouraging results for the Free-energy potential 
method in the prediction of relative ligand binding potency, its application in lead optimization is still at the very 











violation energy Buried surface area
(Kcal mol−1) (Kcal mol−1) (Kcal mol−1) (Kcal mol−1) (Å2)
LumC13 − 83.6 ± 7.3 − 40.9 ± 6.3 − 436.1 ± 24.2 42.4 ± 3.6 21.8 ± 15.74 1290.8 ± 109.1
LumC33ΔC20 − 77.3 ± 11.4 − 45.5 ± 8.0 − 231.0 ± 23.3 31.1 ± 2.8 32.9 ± 9.99 1375.6 ± 140.2
LumC13C-A − 83.8 ± 7.1 − 43.4 ± 3.5 − 153.0 ± 29.2 36.0 ± 7.2 42.1 ± 27.24 1384.9 ± 79.8
LumC13A,Y-F − 84.8 ± 7.0 − 49.8 ± 7.1 − 313.1 ± 40.4 23.8 ± 16.6 37.4 ± 28.55 1574.4 ± 138.3
LumC18ΔC5 − 79.5 ± 1.7 − 48.2 ± 7.2 − 453.9 ± 27.8 42.4 ± 6.1 10.4 ± 5.86 1450.3 ± 71.0
Hybrid 1/3 − 55.8 ± 4.0 − 41.7 ± 9.0 − 307.5 ± 57.5 46.6 ± 10.6 7.9 ± 3.80 1266.2 ± 138.5
Hybrid 2/3 − 76.0 ± 1.6 − 55.2 ± 2.8 − 384.7 ± 11.5 15.5 ± 3.3 6.5 ± 2.02 1441.9 ± 35.8
Hybrid 2/3Y-F − 82.5 ± 0.5 − 44.1 ± 2.5 − 270.4 ± 11.8 24.8 ± 3.9 9.1 ± 2.89 1284.2 ± 24.2
Table 2.  Statistical analysis of the protein-peptide docking result obtained by HADDOCK.
www.nature.com/scientificreports/
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MMPB(GB)SA approaches have become standard for estimation binding free energies since they offer a good 
balance between speed and accuracy. MMPB(GB)SA combines force field based molecular mechanics (MM) with 
a continuum model, based on the Poisson–Boltzmann (PB) or generalized Born (GB) equation to handle elec-
trostatic interactions, and a nonpolar solvation energy correlated with solvent accessible surface area (SA). This 
method can be applied to any aqueous binding process: it is not dependent on assumptions of small (perturba-
tive) differences between two similar systems. The configurational entropy due to ligand–protein binding can be 
calculated by a normal mode (NMODE) method. The MMPB(GB)SA methodology has been applied in various 
Figure 2. C-terminal Lumican peptides bind to the GS-region of ALK5. Peptides average structures after 
minimization bound to ALK5 as depicted in Table 1. ALK5 shown as cyan cartoon, peptides shown as green 
sticks and GS-region depicted in red. Serine forming hydrogen bonds with peptides shown as red sticks.  
(A) LumC13; (B) LumC33Δ20; (C) Lumikine; (D) LumikineY-F; (E) LumC18ΔC5; (F) Hybrid1/3; (G) Hybrid1/3; 
(H) Hybrid2/3; (I) Hybrid2/3Y-F.
www.nature.com/scientificreports/
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small molecule–protein systems, including drugs binding to their receptors26–28. The approach we described here 
is most closely associated with this method.
The contribution of selected residues surrounding the GS domain active site can be clearly seen from Fig. 3. 
For LumC13, Arg5 and Asn13 have significant total energy contributions. Although there are many factors for 
the formation of hydrogen bonds, electrostatic interactions play a major role. As described above, the relationship 
between the hydrogen bond and electrostatic term are discussed qualitatively. In fact, several hydrogen bonds are 
easily formed because of strong electrostatic interactions. From the ALK5 GS domain region, Glu247, Ser187, 
Gly192, Thr251 and Ser191 have prominent electrostatic contributions evidenced by lower values of Δ Eele (− 4.97, 
− 7.75, − 26.15, and − 47.13 kcal mol−1, respectively), and are correlated to the formation of several hydrogen 
bonds with LumC13 qualitatively, as shown in Fig. 2 and Supplemental Fig. S1.
The strongest electrostatic contribution comes from the GS domains and the helix 8 located on its oppo-
site site, which promotes one strong H-bond in complex. The lowest averaged value of Δ Eele (− 7.13 kcal mol−1) 
implies that Ser187 might make a special contribution for active site of GS-domain. Strong electrostatic interac-
tions result in the formation of hydrogen bonds between ALK5 and Asp7 and Glu2 in LumC13, LumC13C-A and 
LumC13AY-F.
LumC13 Asp9 has the strongest electrostatic contribution, which promotes one strong H-bond in complex. 
The lowest value of Δ Eele (− 47.13 kcal mol−1) implies that this residue might make a special contribution for 
peptide binding. Peptides outside EVTLN domain region reduced the binding by 10,000- fold (value of kcat/Km 
is 1.0 ± 0.004 and < 0.0001 s−1 μ M−1 in LumC13 and LumC33ΔC20, respectively. In addition, Val10 and Leu12 
of LumC13/Lumikine are close to ALK5 Gly182, and two electrostatic interactions exist, which leads to two 
H-bonds. Ser180, with a Δ Eele of − 7.75 kcal mol−1, has two electrostatic interactions with the ligand because of 
the close proximity between Gly183 and Val3, which promote two H-bonds, as shown in Fig. 3.
The van der Waals contribution of some residues in the region surrounding the GS-domain, particularly 
Gln250 and Thr251, play the main role in the total protein-peptide contributions (Fig. 3A–F). Of these residues, 
Gln250 has the strongest van der Waals contribution of − 3.76 kcal mol−1. In addition, the free energy calcula-
tion results show that ALK5 Thr251 van der Waals contributions are also significant to the system as a whole. 
Throughout the energetic decomposition and probability of occurrence of hydrogen bonds, we determined that 
the most fundamental binding residues in the ALK5 GS domain were Asp183, Gly188, Ser189, Gly190, Ser191, 
and Ser187. The major contributions of Gly-Ser region originate from electrostatic interactions and those of 
Asp183 and Gln247 were from a van der Waals’ interactions. Figure 3 shows residues at binding sites with appre-
ciable electrostatic contributions, with all Δ Eele of < − 20 kcal mol−1. Strong electrostatic interactions result in the 
formation of hydrogen bonds between ALK5 and peptides containing the EVTLN region. It is noted that Y6 from 
peptide Hybrid 2/3 also makes a positive electrostatic contribution to the system. However, with Hybrid 2/3Y-F 
there is no H-bond formation between Phe9 and the residues around the GS domain.
Although there is no direct H-bond forming with Hybrid 2/3Y-F, Pro2 and Pro3 electrostatic contributions 
secure peptide binding to the GS-region. Strong electrostatic interactions might result in the formation of hydro-
gen bonds between these residues and the GS-domain as depicted in Fig. 3. ALK5 Ser189 has the highest van 
der Waals contribution at − 12.53 kcal mol−1. Throughout the whole energetic decomposition and probability of 
occurrence of hydrogen bonds, we determined that the most vital binding residues at the GS-domain were the 
ones before mentioned.
When the decomposition of the binding energy of the residues in both domains were compared, we found 
that the similar van der Waals’ interactions are found in peptides containing the EVTLN region. Nonetheless, the 
substitution of Y9 to F mutation in Hybrid2/3Y-F has an evident impact in electrostatic forces for the GS-domain 
binding; however, the magnitude of electrostatic term in the C-terminal domain was larger. The strength of the 
binding ability between each peptide and GS-domain cannot be determined clearly so far; thus, it is necessary to 
call for further studies and discussion about total binding energy of these complex systems. As mentioned above, 
the total binding energy of ALK5–LumC peptides complex systems are an important standard measure of binding 
affinity between each domain and ALK5. Total binding free energies for the two complex systems were calculated 
by MM-PBSA. The MMPBSA results are listed in Fig. 3. The Δ Gtotal can be divided into polar and nonpolar ener-
gies. The free energies of ALK5 binding to the peptides were primarily derived from the polar energies (equal to 
Δ Gele,sol + Δ Eele), which were − 218.0 kcal mol−1 in LumC-ALK5 complexes and − 446.3 kcal mol−1 in Hybrid 
2/3–ALK5 complex (Fig. 3). However, for both complexes, the nonpolar energy (equal to Δ Gnonpolar,sol + Δ Evdw) 
shows negative contributions at 134.9 and 378.3 kcal mol−1 for LumC13 and Hybrid 2/3Y-F, respectively, which 
largely cut down the total contribution. Thus, the values of Δ Gtotal for LumC13 and Hybrid 2/3Y-F are − 83.1 and 
Peptide Acceptor Donor Presence (%)
LumC13 Gln N-H Tyr OH 94.37%
LumC30ΔC20 Gly247 COO- Arg N-H 61.29%
LumC13C-A ValC-O Gln N-H 89.35%
LumC13AY-F ValC-O Gln N-H 66.94%
LumC18ΔC5 Asp COO- Lys N-H 52.19%
Hybrid 1/3 ValC-O Lys N-H 63.44%
Hybrid 2/3 Asp COO- Lys N-H 71.84%
Hybrid 2/3Y-F Asp COO- Lys N-H 87.15%
Table 3.  Hydrogen Bond occupancies for the lumikine peptides-ALK5 complex.
www.nature.com/scientificreports/
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Figure 3. Per-residue energy contributions to the formation of lumican-ALK5 complexes. Free energy of 
bound lumikine and lumican peptides to TGFBRI/ALK5. ALK5 residues are shown as blue lines and peptide 
shown as red bars. Error bars were not included since standard errors were always.
www.nature.com/scientificreports/
8Scientific RepoRts | 7:42057 | DOI: 10.1038/srep42057
− 68.0 kcal mol−1, respectively, which indicates that ALK5 has a stronger binding interaction to this hybrid than 
the LumC13/Lumikine peptide. We qualitatively studied the difference in terms of binding energy between the 
peptide and ALK5 domains; which indicated that the LumC13 has a stronger ability than the N-terminal pep-
tides to bind to ALK5, which is in good agreement with our conclusion. In addition, the relative affinities of the 
C-terminal active sites of Lumican were very similar; thus, the difference in total binding energy between each 
domain and ALK5 might just be consistent with that C-terminal region.
In short, computational methods identified peptide Hybrid 2/3 as capable of binding ALK5 domain with 
the lowest interactions energies, and that binding depends on the EVTLN domain. The computational studies 
predicted that although LumC peptide derivatives bind to ALK5 binding and pose as a potential new target for 
promoting wound healing. In order to further improve the peptides affinity, we subsequently attempted to modify 
and optimize the primary sequence of the peptide. The designed peptides were assayed in vivo to determine capa-
bility to promote wound healing using a debridement wound healing model. As our computational studies pre-
dicted, peptides Lum13/LumC-A and Hybrid 2/3 exhibit an increased ability to promote wound healing. Hybrid 
2/3 possesses the highest affinity in all designed peptides (Kd = 28.7 ± 3.9 lM), and thus can be considered as a 
promising lead to develop peptide therapeutics targeting wound healing.
Peptide Delivery via Eye Drop to Mouse Cornea after Epithelial Debridement. To confirm pep-
tide action promoting corneal epithelium wound healing in vivo, mice were subjected to a 2 mm with corneal 
epithelium debridement. The injured corneas were treated with 10 μ l eye drops lumican peptides (0.3 μ M) every 
15 min for 5 h as previously described6. Migration distance was measured between the original wound edge and 
the wound front. In Lumikine (LumC13C-A) treated corneas, the epithelium sheet moved ∼ 144 μ m. The control 
peptide, LumC30Δ C20, did not promote epithelium wound healing, whereas peptide hybrid 2/3 promotes wound 
migration of about 107 μ m. The average epithelium migration (μ m) and standard deviation were calculated from 
n corneas of each of two separate experiments.
Lum null (Lum−/−) mice were also used to examine the efficacy of LumC peptides in promoting epithelium 
sheet migration following debridement wound (Supplemental Fig. S2). Figure 4 shows that the administration of 
LumC13C-A promoted wound healing of corneal epithelium debridement of Lum−/− mice to the same extent as 
injured wild type mice as previously shown6. Treatment with Hybrid 2/3 also increased the epithelium migration 
(~110 μ m) while the substitution of Y to F abolished the epithelial migration promoting activity. Interestingly, 
administration of LumC33Δ20, LumC18ΔC5, and Hybrid1/3 had little effect promoting wound healing, suggest-
ing that the C-terminal domain of EVTLN is essential for promoting epithelium migration of injured cornea. 
LumC13 had moderately increased activity in promoting wound healing when compared to LumC13C-A. Mass 
spectrometry revealed the higher pharmaceutical activity of LumC13C-A compared to LumC13 was due to the 
dimerization of the LumC13 peptides in solution via disulfide bond formation of cysteine residue, which reduces 
the activity of dimerized LumC13. The summarized data from different treatments shows each treatment includ-
ing at least five or more eyes from two separate experiments. These results showed that both the LumC13C-A and 
Hybrid 2/3 peptides significantly promoted epithelium wound healing.
Discussion
This study depicts the different binding energies of different 13 amino acid LumC peptides to ALK5 by combining 
molecular dynamics results and docking conformational changes. Our computational data was then confirmed 
in vivo using a corneal epithelial wound healing model. In all models, several pairs of hydrogen bonds are found 
in the region around the ALK5 GS-region, such as the hydrogen bond between the N of residue Gly188 and 
hydroxyl side-chain oxygen of LumC13 Glu9 and the hydroxyl of Thr251, as well as the side chain oxygen of 
Gln250. Analyses of contribution of the binding free energy and its decomposition into per-residue indicate that 
the conformational changes of the region around the GS-domain region is a receptor for binding of the Lumikine.
Figure 4. In vivo wound healing activity of Lumican peptides. Corneal epithelium debridement wound 
healing in vivo. The average epithelium migration per hour (μ m/h) and standard deviation were calculated from 
n corneas of each of two separate experiments. *< 0.005; ‡Hybrid 2/3 is 0.092 that is p < 0.05; LumC13A Y-F is 
0.122 that is p < 0.05. Statistical analysis was performed using ANOVA.
www.nature.com/scientificreports/
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Injured mouse corneal epithelial cells ectopically and transiently expresses lumican during the acute phase of 
wound healing18,29–33. Thereafter, the degradation of Lumican by MMPs within the extracellular space of the cor-
neal epithelium34,35, such as MT1-MMP, leads to the distribution of Lumican products throughout the wounded 
area, which could have potential pharmacological relevance. Therefore, we explored the potential of Lumican 
peptides to bind to a previously established Lumican surface receptor, ALK5/TGFbRI, which has been shown to 
strongly enhance skin and cornea wound healing6,36.
We have previously shown that Lumican promotes wound healing via its C-terminal domain due to its inter-
action with TGFβ RI (ALK5), preventing further canonical TGFβ signaling via Smad cascade following polymeri-
zation of TGFBR2 and ALK5/TGFBR16. In this present study, we have accessed the binding of rationally designed 
LumC peptides with a related scoring approach, MM-GBSA, after docking and molecular dynamics simulations. 
In this method, docking scores are used to define initial binding sites, and more expensive and rigorous methods 
such as molecular dynamics (MD) simulation and binding free energy (BFE) calculations are employed to study 
these interactions37–39. These computational methods are considered accurate, as factors such as flexibility of the 
complex and solvation effects are taken into account. Whereas several studies have shown the successful appli-
cation of binding free energy approaches in predicting binding modes for diverse molecules at binding pockets 
of target proteins40–42. However, a comprehensive streamline methodology of rational design, in silico evaluation 
and validation have not yet been widely applied to predicting the binding mode of protein–peptide complexes in 
their potential use as inhibitors.
Here, we evaluated the binding free energy after decomposition into per-atom contributions, which could 
be summed over atom groups to obtain different energy contributions arising from residues backbone and 
side-chain by using the MMGBSA method, which is particularly useful to explore the variability of these peptides. 
After applying in silico methodology, peptides were successfully tested experimentally for their propensity to pro-
mote in vivo wound healing after binding TGFBRI. The most potent of these peptides exhibited activity in an in 
vivo model of corneal epithelium debridement. With the in vitro evidence for modeling experiments, our analysis 
suggests that lumikine binding is targeted to the GS-domain of ALK5. Conclusions based on these simulations 
should take into account the effect of peptide initial conformations; although multiple copies of trajectories on the 
100-ns timescale (enhanced sampling) may still affect the simulation results. The exploration of the contribution 
of binding free energy and its decomposition into per-residue analysis indicate that the conformational changes 
of the region around the GS-domain play an important role in understanding of the binding affinity to the LumC 
peptides.
Our data also demonstrates great pharmacological applications of using LumC13 derivatives for promoting 
the rate of wound healing. This could be of particular interest in conditions where patients display delayed wound 
healing, such as diabetes, which culminates in an increased risk of inflammation and scarring. The significance 
of synthesizing lumican peptides that mediate TGFbRI signaling also goes beyond promoting skin and corneal 
wound healing. We have previously demonstrated that lumican inhibits prostate cancer cell migration, and thus 
is mediated through the TGFβ signaling pathway1,3. Our group recently reviewed the role of SLRPs, including 
lumican, on pathogenesis5. Thus, Lum peptides could also be targeted for other malignancies such as limiting the 
spread of certain types of cancer cells.
Our approach represents a fast and straightforward approach that can be applied as a general method to deter-
mine binding modes of protein− peptide complexes and also to design TGBβ RI inhibitors.
Conclusion
An in silico approach combining molecular docking and molecular dynamics was successfully used to predict 
minimal lumican amino acid sequence necessary for forming a stable complex with ALK5/TGFbRI. In vitro and 
in vivo wound healing assays demonstrated that LumC13, markedly the EVTL motif, is essential to promote epi-
thelial cell migration to the same extent as lumican, thereby confirming the in silico data.
Experimental Section
In vivo healing of epithelium debridement. Use of experimental mice is in compliance to the ARVO 
statement for the use of animals in vision research and all procedures are approved by IACUC of the University 
of Cincinnati. Lum−/− mice in C57BL/6 genetic background aged 7–8 weeks were used in this study. Mice were 
anesthetized with intraperitoneal injections of a combination of ketamine (10 mg/kg; Henry Shein) and xylazine 
(1 mg/kg; Henry Shein) prior to the surgery, and a drop of proparacaine hydrochloride 0.5% (Alcon) was applied 
to the cornea to deliver local anesthesia before injury. Briefly, a 2 mm diameter trephine was used to demar-
cate the central epithelial region of the eye and the epithelium within the demarcated region was mechanically 
removed using an Algerbrush II (Alger Equipment Co., Inc., Lago Vista, TX) while viewing the cornea under a 
stereomicroscope (Stemi SC II stereomicroscope with epi-fluorescence attachment, Carl ZEISS). Eight mice per 
group were treated and the experiments were repeated at least two times. Each mouse was topically treated with 
one drop peptide solution (10 μ l) at concentration of 0.3 μ M or 10 μ L PBS every 15 min for 5 h after wounding. 
After 5 h, mice were sacrificed. The eyes were excised and fixed in 4% paraformaldehyde in PB (0.1 M phos-
phate buffer, pH 7.4. whole mount corneas were stained with phalloidin and DAPI and image with a Zeiss Apo 
Tome microscope (Observer Z1). The migration of epithelium sheet was determined as previously described5,6. 
In brief, migrated corneal epithelium was measured on whole mount samples in 5 different locations equally 
distributed around the entire circumference of the wound. The number of animals in each experimental group 
is on the bars in the bar chart. The statistical analyses as well as symbols are shown in the graph legend. PBS 
treated Lum−/− mice were used as negative controls, in which the epithelium sheet migrated less than 50 μ m in 
5 h (Supplemental Fig. 2 for representative plots). Four Z-staged images were collected from each corneas, the 
epithelium migration was determined by the distance of migration of epithelium front to the initial injured line 
as previously described.
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Peptide–protein flexible dockings. The peptide sequence used in the ALK5 docking studies was derived 
from a part of Lum C-terminal region consisting of residues from amino acids 321–338, as it was previously used 
in the activity measurements conducted by our group6,43. The ALK5 complex models were generated using a 
two-phase docking protocol using HADDOCK web server http://haddock.chem.uu.nl/44. In the first phase, the 
LumC peptides were docked onto the structure of ALK5 with a three-step protocol for performing the docking 
calculations. First, one thousand structures were generated during rigid body docking stage, of which the best 100 
structures based on their intermolecular energy were submitted to the second stage of semi flexible refinement. 
All 100 structures were then refined in the third stage using an explicit solvent (in water) and were clustered based 
on the root mean square deviation (RMSD). HADDOCK scoring was performed according to the weighted sum 
(HADDOCK score) of different energy terms, which include van der Waals energy, electrostatic energy, dis-
tance restraints energy, inter-vector projection angle restraints energy, diffusion anisotropy energy, dihedral angle 
restraints energy, symmetry restraints energy, binding energy, desolvation energy and buried surface area. Along 
with the HADDOCK score, we calculated the van der Waals energy, electrostatic energy, restraints violation 
energy, desolvation energy and buried surface area.
The best pose clustered in the best binding region returned by the rotational blind docking was used as start-
ing conformation. Accordingly, flexible docking protocols Rosetta FlexPepDock Web Server45 and Cluspro46 were 
used to study and compare the allosteric interactions retrieved among themselves. For the eight ALK5/peptide 
complexes, the top ten poses with the highest scores were found to be very similar, and the one with the highest 
score was chosen for refinement with MD. Hybrid peptides were rationally designed by including other regions of 
the C-terminal domain of Lumican that bind to ALK56 and modeled using PEP-FOLD47.
Each complex structure solvated with 17,216 water molecules and 0.1 M KCl. After pressure coupling, individ-
ual protein-peptides complexes were gradually relaxed in 50-ns MD simulations, where convergence was mon-
itored using the RMSD of the backbone atoms. MD simulations were performed using the NAMD program48 
with the CHARMM27 force field49. An NpT ensemble was used with the temperature and pressure maintained 
at 300 K and 1 atm, respectively, via Langevin coupling with damping coefficients of 5 ps−1 and 10 ps−1. Periodic 
boundary conditions were employed together with particle-mesh Ewald algorithm to compute the long-range 
electrostatic interactions. Lennard-Jones (LJ) interactions were switched off within a distance of 10–12 Å, and 
the list of non-bonded interactions was truncated at 13.5 Å. A time step of 2 fs was used, and the trajectory data 
were written at 1 ps intervals. Intermolecular contacts (hydrogen bonds and non-bonded contacts) were analyzed 
with the LIGPLOT software50. The default settings were used (3.9 Å heavy atoms distance cut-off for non-bonded 
contacts; 2.7 and 3.5 Å proton–acceptor and donor–acceptor distance cut-offs, respectively, with minimum 90° 
angles (D–H–A, H–A–AA, D–A–AA) for hydrogen bonds)51.
MM/PBSA binding free energy calculations: To determine the most stable complexes predicted by the 
molecular docking, the binding free energy (Δ Gbind) for each complex was estimated by using the MM/PBSA 
approach previously based on the snapshots extracted from the single trajectory of the complex (single trajectory 
method)25,52, producing precise and reproducible free energy estimates for peptide-protein simulations28,53,54. 
Accordingly, the binding free energy of the peptides to ALK5 in solution was defined by the following equation55.
∆ = − −
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bind complex protein ligand
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where Δ EMM is the interaction energy between protein and ligand in the gas-phase, including the parts: the van 
der Waals energies (∆ Evdw) and the electrostatic (∆ Eele); ∆ GGB and ∆ GSA are the relative polar and nonpolar 
contributions to desolvation free energy, respectively, and [− T∆ S] represents the conformational entropic con-
tribution at temperature T. In this work, Δ Gpolar and Δ Gnonpolar were calculated with APBS56. Finally, the binding 
free energy of each system was calculated based on 300 snapshots from the last 30 ns MD simulation trajectories 
of each complex by using the mm_pbsa program in Gmxpbsa57.
Free energy decomposition analysis. To properly evaluate individual residue influence in the interaction 
between ALK5 and LumC peptides, a free energy decomposition process was applied to the mm_pbsa analysis. 
During the decomposition process, the polar contribution of desolvation free energy (∆ GGB) was calculated using 
the generalized Born (GB) approximation model developed by Onufriev et al.45, and the nonpolar solvation con-
tribution (∆ GSA) part was computed based on the SASA determined with the ICOSA algorithm58. Energy com-
ponents were from snapshots as described above, resulting in residue-allocated peptide free energy contributions 
from the association with its receptor.
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